Determining the best course of treatment for younger patients with relapsed/refractory CLL

Determining the best course of treatment for younger patients with relapsed/refractory CLL

User Photo
VJHemOnc

2 years
129 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The optimal treatment for younger patients with relapsed/refractory chronic lymphocytic leukemia (CLL) depends on a number of factors, including what was given as the frontline treatment. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the options available to this group on patients. Dr Davids covers the prospect of continuing chemoimmunotherapy, the agents he typically advises, alternative options and what he predicts to be the case in the future.
Up Next Autoplay